DK3624831T5 - Rekombinant human sur alfa-glucosidase - Google Patents

Rekombinant human sur alfa-glucosidase Download PDF

Info

Publication number
DK3624831T5
DK3624831T5 DK18802722.1T DK18802722T DK3624831T5 DK 3624831 T5 DK3624831 T5 DK 3624831T5 DK 18802722 T DK18802722 T DK 18802722T DK 3624831 T5 DK3624831 T5 DK 3624831T5
Authority
DK
Denmark
Prior art keywords
glucosidase
recombinant human
acid alpha
human acid
alpha
Prior art date
Application number
DK18802722.1T
Other languages
English (en)
Other versions
DK3624831T3 (da
Inventor
Hung Do
Russell Gotschall
Richie Khanna
Yi Lun
Hing Char
Sergey Tesler
Wendy Sunderland
Enrique Diloné
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Application granted granted Critical
Publication of DK3624831T3 publication Critical patent/DK3624831T3/da
Publication of DK3624831T5 publication Critical patent/DK3624831T5/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102Alpha-glucosidase (3.2.1.20)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
DK18802722.1T 2017-05-15 2018-05-15 Rekombinant human sur alfa-glucosidase DK3624831T5 (da)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201762506561P 2017-05-15 2017-05-15
US201762506569P 2017-05-15 2017-05-15
US201762506574P 2017-05-15 2017-05-15
US201762529300P 2017-07-06 2017-07-06
US201762564083P 2017-09-27 2017-09-27
US201762567334P 2017-10-03 2017-10-03
US201862618021P 2018-01-16 2018-01-16
US201862624638P 2018-01-31 2018-01-31
US201862660758P 2018-04-20 2018-04-20
PCT/US2018/032815 WO2018213340A1 (en) 2017-05-15 2018-05-15 Recombinant human acid alpha-glucosidase

Publications (2)

Publication Number Publication Date
DK3624831T3 DK3624831T3 (da) 2023-06-26
DK3624831T5 true DK3624831T5 (da) 2024-09-02

Family

ID=64274660

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18802722.1T DK3624831T5 (da) 2017-05-15 2018-05-15 Rekombinant human sur alfa-glucosidase

Country Status (24)

Country Link
US (1) US20210393747A1 (da)
EP (2) EP4223310A3 (da)
JP (2) JP7193476B2 (da)
KR (1) KR20200004414A (da)
CN (1) CN111356474A (da)
AU (1) AU2018270925A1 (da)
BR (1) BR112019024125A2 (da)
CA (1) CA3063615A1 (da)
CL (1) CL2019003251A1 (da)
DK (1) DK3624831T5 (da)
ES (1) ES2950808T3 (da)
FI (1) FI3624831T3 (da)
HR (1) HRP20230576T1 (da)
HU (1) HUE062504T2 (da)
IL (2) IL270530B2 (da)
LT (1) LT3624831T (da)
MX (1) MX2019013624A (da)
PL (1) PL3624831T3 (da)
PT (1) PT3624831T (da)
RS (1) RS64301B1 (da)
SI (1) SI3624831T1 (da)
TW (1) TW201900208A (da)
WO (1) WO2018213340A1 (da)
ZA (1) ZA201907552B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ760232A (en) 2017-06-07 2023-05-26 Regeneron Pharma Compositions and methods for internalizing enzymes
EP3871687A1 (en) * 2020-02-27 2021-09-01 eleva GmbH Enzyme replacement therapy for treating pompe disease
IL305103A (en) * 2021-02-11 2023-10-01 Amicus Therapeutics Inc Recombinant human acid alpha glucosidase and uses thereof
CN114280182A (zh) * 2021-12-23 2022-04-05 福建省中医药科学院 一种太子参均一多糖的hplc-fld检测方法
WO2023150387A1 (en) * 2022-02-07 2023-08-10 M6P Therapeutics, Inc. Compositions comprising acid alpha glucosidase and methods of use thereof
WO2023215865A1 (en) * 2022-05-05 2023-11-09 Amicus Therapeutics, Inc. Methods for treating pompe disease
WO2024119070A1 (en) * 2022-12-02 2024-06-06 Amicus Therapeutics, Inc. Methods for treating late onset pompe disease in pediatric patients
WO2024119091A1 (en) * 2022-12-02 2024-06-06 Amicus Therapeutics, Inc. Fexamethods for treating infantile-onset pompe disease in pediatric patients

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
PT3470077T (pt) 2008-02-12 2020-11-30 Amicus Therapeutics Inc Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonas
CA2775938C (en) * 2009-09-29 2021-08-10 Oxyrane Uk Limited Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
WO2013070953A1 (en) * 2011-11-08 2013-05-16 University Of Washington Lysosomal enzyme assay methods and compositions
KR20140135222A (ko) * 2012-03-07 2014-11-25 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
WO2014110270A1 (en) * 2013-01-09 2014-07-17 Amicus Therapeutics, Inc. Stable parenteral dnj compositions
PT3201320T (pt) * 2014-09-30 2024-01-12 Amicus Therapeutics Inc Alfa-glucosidase ácida altamente potente com hidratos de carbono intensificados
WO2017049161A1 (en) * 2015-09-18 2017-03-23 Duke University ACID ALPHA-GLUCOSIDASE AND A β-2 AGONIST FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDER
KR102510941B1 (ko) * 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
MX2018011951A (es) * 2016-03-30 2019-02-13 Amicus Therapeutics Inc Metodo para seleccionar proteinas recombinantes ricas en m6p.

Also Published As

Publication number Publication date
IL270530B2 (en) 2024-07-01
KR20200004414A (ko) 2020-01-13
AU2018270925A1 (en) 2019-11-28
EP3624831A4 (en) 2021-02-17
EP3624831A1 (en) 2020-03-25
WO2018213340A1 (en) 2018-11-22
US20210393747A1 (en) 2021-12-23
EP4223310A3 (en) 2023-10-11
PT3624831T (pt) 2023-07-04
CL2019003251A1 (es) 2020-05-22
HUE062504T2 (hu) 2023-11-28
TW201900208A (zh) 2019-01-01
BR112019024125A2 (pt) 2020-06-02
CN111356474A (zh) 2020-06-30
IL310719A (en) 2024-04-01
IL270530A (en) 2020-01-30
ZA201907552B (en) 2024-09-25
IL270530B1 (en) 2024-03-01
EP3624831B1 (en) 2023-03-29
PL3624831T3 (pl) 2023-08-14
MX2019013624A (es) 2020-01-13
ES2950808T3 (es) 2023-10-13
CA3063615A1 (en) 2018-11-22
HRP20230576T1 (hr) 2023-09-01
JP2023051927A (ja) 2023-04-11
SI3624831T1 (sl) 2023-08-31
EP4223310A2 (en) 2023-08-09
DK3624831T3 (da) 2023-06-26
FI3624831T3 (fi) 2023-06-12
JP7193476B2 (ja) 2022-12-20
LT3624831T (lt) 2023-07-10
JP2020519638A (ja) 2020-07-02
RS64301B1 (sr) 2023-07-31

Similar Documents

Publication Publication Date Title
DK3624831T3 (da) Rekombinant human sur alfa-glucosidase
MA42036A (fr) Analogues nucléosidiques 5'-substitués
DK3705102T3 (da) Patientløftesystem
KR20180084839A (ko) 임베딩된 비아 없는 브릿지들
IL294012A (en) Formulations that include recombinant acid alpha-glucosidase
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
IT201700111007A1 (it) Discensore
DK3259358T3 (da) Forøget proteinekspression
DK3592297T3 (da) Vævsteknologistilladser
BR112017018419A2 (pt) endoscópio flexível
DK3630793T3 (da) Rekombinant protein
DE112018006474A5 (de) Endoskop
JP1628025S (ja) 検眼器
JP1628024S (ja) 検眼器
FI11901U1 (fi) Paistinlasta
UA37888S (uk) Шпатель
UA37893S (uk) Шпатель
UA37886S (uk) Шпатель
IT201700101911A1 (it) Materasso invernale
UA35128S (uk) Вулик
LT3436053T (lt) Kompozicijos, apimančios rekombinantinę rūgštinę alfa-gliukozidazę
DK3399899T3 (da) Håndholdt endoskop
ITUA20162755A1 (it) Struttura articolata
ITUA20162672A1 (it) Video-endoscopio odontoiatrico
DK3247719T3 (da) Met-receptoragonistproteiner